{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:29:22Z","timestamp":1758122962715},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3,15]]},"DOI":"10.2146\/ajhp120602","type":"journal-article","created":{"date-parts":[[2014,3,3]],"date-time":"2014-03-03T21:25:19Z","timestamp":1393881919000},"page":"453-462","source":"Crossref","is-referenced-by-count":10,"title":["Ruxolitinib for the treatment of primary myelofibrosis"],"prefix":"10.1093","volume":"71","author":[{"given":"Starla J.","family":"Swaim","sequence":"first","affiliation":[{"name":"Leukemia, Division of Pharmacy, University of Texas, M. D. Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"2019041210511608100_b1-0710453","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev.med.60.041707.160528","article-title":"Primary myelofibrosis: update on definition, pathogenesis, and treatment","volume":"60","author":"Abdel-Wahab","year":"2009","journal-title":"Annu Rev Med"},{"key":"2019041210511608100_b2-0710453","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","article-title":"Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001\u20132004, using data from the NAACCR and SEER programs","volume":"112","author":"Rollison","year":"2008","journal-title":"Blood"},{"key":"2019041210511608100_b3-0710453","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2141.1990.tb02609.x","article-title":"Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients","volume":"75","author":"Visani","year":"1990","journal-title":"Br J Haematol"},{"key":"2019041210511608100_b4-0710453","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"2019041210511608100_b5-0710453","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"2019041210511608100_b6-0710453","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"key":"2019041210511608100_b7-0710453","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"key":"2019041210511608100_b8-0710453","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia","volume":"342","author":"Tefferi","year":"2010","journal-title":"N Engl J Med"},{"key":"2019041210511608100_b9-0710453","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/ajh.22210","article-title":"Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management","volume":"86","author":"Tefferi","year":"2011","journal-title":"Am J Hematol"},{"key":"2019041210511608100_b10-0710453","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2141.2004.05229.x","article-title":"Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature","volume":"127","author":"Cervantes","year":"2004","journal-title":"Br J Haematol"},{"key":"2019041210511608100_b11-0710453","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1365-2141.2006.06142.x","article-title":"Darbepoietin-alpha for the anaemia of myelofibrosis with myeloid metaplasia","volume":"134","author":"Cervantes","year":"2006","journal-title":"Br J Haematol"},{"key":"2019041210511608100_b12-0710453","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1517\/14656566.2013.783019","article-title":"Myelofibrosis: an update on curent pharmacotherapy and future directions","volume":"14","author":"Cervantes","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"2019041210511608100_b13-0710453","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1182\/blood-2010-11-315614","article-title":"How I treat myelofibrosis","volume":"117","author":"Tefferi","year":"2011","journal-title":"Blood"},{"key":"2019041210511608100_b14-0710453","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.4971.4971","article-title":"Hydroxyurea effect on marked splenomegaly associated with primary myelofibrosis: response rates and correlation with JAK2V617F allele burden","volume":"114","author":"Siragusa","year":"2009","journal-title":"Blood"},{"key":"2019041210511608100_b15-0710453","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.22021","article-title":"Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic","volume":"107","author":"Mesa","year":"2006","journal-title":"Cancer"},{"key":"2019041210511608100_b16-0710453","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/blood.V95.7.2226","article-title":"Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients","volume":"95","author":"Tefferi","year":"2000","journal-title":"Blood"},{"key":"2019041210511608100_b17-0710453","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1054\/blre.1999.0110","article-title":"Splenic irradiation in the melofibrosis with myeloid metaplasia: a review","volume":"13","author":"Elliott","year":"1999","journal-title":"Blood Rev"},{"issue":"suppl","key":"2019041210511608100_b18-0710453","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1179\/102453312X13336169156375","article-title":"JAK2 inhibitors and their impact in myeloproliferative neoplasms","volume":"17","author":"Geyer","year":"2012","journal-title":"Hematology"},{"key":"2019041210511608100_b19-0710453","volume-title":"Jakafi (ruxolitinib) package insert","year":"2011"},{"key":"2019041210511608100_b20-0710453","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1600-065X.2008.00644.x","article-title":"Therapeutic targeting of Janus kinases","volume":"223","author":"Pesu","year":"2008","journal-title":"Immunol Rev"},{"key":"2019041210511608100_b21-0710453","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1177\/0091270010389469","article-title":"The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers","volume":"51","author":"Shi","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"2019041210511608100_b22-0710453","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1124\/dmd.110.033787","article-title":"Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1\/2 inhibitor, in humans","volume":"38","author":"Shilling","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"2019041210511608100_b23-0710453","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1177\/0091270011405663","article-title":"The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers","volume":"52","author":"Shi","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"2019041210511608100_b24-0710453","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"key":"2019041210511608100_b25-0710453","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMc1109555","article-title":"Long-term outcome of treatment with ruxolitinib in myelofibrosis","volume":"365","author":"Tefferi","year":"2011","journal-title":"N Engl J Med"},{"key":"2019041210511608100_b26-0710453","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood-2012-02-414631","article-title":"Long-term outcomes of 107 patients with myelofibrosis receiving JAK1\/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls","volume":"120","author":"Verstovsek","year":"2012","journal-title":"Blood"},{"key":"2019041210511608100_b27-0710453","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","article-title":"International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"key":"2019041210511608100_b28-0710453","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"2019041210511608100_b29-0710453","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"key":"2019041210511608100_b30-0710453","unstructured":"Incyte Corporation. IncyteCARES: support for patients with myelofibrosis. www.jakafi.com\/IncyteCARES (accessed 2013 Dec 16)."},{"key":"2019041210511608100_b31-0710453","volume-title":"Red book online (Internet database)"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/71\/6\/453\/28372308\/ajhp0453.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T23:32:20Z","timestamp":1597534340000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/71\/6\/453\/5111147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,15]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,3,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp120602","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,3,15]]},"published":{"date-parts":[[2014,3,15]]}}}